Emami’s consolidated revenues grew by 12% on a like-like basis (in-line) driven by 9% volume growth. We were surprised with EBITDA/APAT decline of -3/-5% vs. expectation of 9/3% respectively. Domestic business grew by 10% driven by growth in Navratna/Pain Management/Male Grooming/Kesh King hair oil of 14/13/8/11%. Boroplus (off-season) and Healthcare range (impacted by Pancharishtha) disappointed as both declined by 2%. International business bounced back with 37% growth, albeit with a favorable base (-38%). MENAP and SAARC (combined 75% of international) regions picked up growth after lackluster performance in the previous quarters.
OutlookWe value Emami based on P/E of 36x on Mar-20 EPS to arrive at a TP of Rs 1,230. We maintain BUY.
For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!